PharmaCyte Biotech Inc (PMCB)

[1234jklm]

I don’t think so musky.

I’ve been in touch with some people at jdrf and I’ve changed my view on our position with diabetes.

I think the reality is that there are no peer reviewed studies of our technology published so the industry doesn’t see it as a valid technology for diabetes yet. That seems to be jdrf’s position on us from the little I can glean from them.

Without peer reviewed published articles we are not seen as a real contender.

The work on establishing whether insulin producing cells can survive in our encapsulation hasn’t been done or hasn’t been reported.

The proof isn’t there.

The pancreatic cancer trials will move that forward but I think in terms of diabetes we are losing the race through lack of published trials.

Sigilon may well fail because alginate has many issues that haven’t yet been tested in humans but they are far far ahead of us because of the work done by mit on this technology and it’s ability to evade the fibrotic reaction due to its special coating. It can also be frozen and transported. But there are many many more issues to be faced.

But they’ve had peer reviews studies published in Nature and they have Robert Langer behind them supervising the work. They have results and credibility and we have promises and no results.

We’ve been told for years that diabetic studies are taking place but we’ve heard nothing for a very long time except that mellingen cells have failed. When was the last time the diabetes consortium met?

The inclusion of stem cells producing insulin in our new agreement with Austrianova is encouraging but until we have peer reviewed reports on this big pharma isn’t going to take it seriously.

The information about ciab studies with diabetic rats has been removed from the Austrianova website. Does anyone have that report?